This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
SIU 2017
SIU 2017 Kidney Cancer
SIU 2017
Prostate Cancer
Kidney Cancer
Bladder Cancer
Conferences
Viewing 701-720 of 11869 articles
AUA 2024: A Multi-Center Randomized Controlled Trial Of Ambulatory Versus Inpatient Percutaneous Nephrolithotomy
AUA 2024: Outcomes for Localized Renal Cell Carcinoma Patients on Immunosuppression Following Organ Transplantation
AUA 2024: Does Deep Learning Reconstruction Improve Ureteral Stone Detection and Subjective Image Quality in the CT Images of Patients with Metal Hardware?
AUA 2024: The Role of PSA Doubling Time in the Stratification of Patients with a Negative PSMA PET After Biochemical Recurrence of Prostate Cancer: Implications for Tailored Salvage Treatment Strategies
AUA 2024: Evaluating the Role of Telemedicine in Reducing Racial and Ethnic Disparities in Prostate Cancer Care
AUA 2024: Descriptive Tumor Characteristics of 992 Consecutive Patients Who Underwent Staging with PSMA PET/CT Before Radical Prostatectomy.
AUA 2024: Greening the Operating Room (GOR): High-Impact Initiatives Urologists’ Can Facilitate to Jumpstart a Program
AUA 2024: ARV-766, a PROTAC Androgen Receptor Degrader, Combined with Abiraterone in Novel Hormonal Agent (NHA)-Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 Study
AUA 2024: Determinants of Financial Toxicity in Patients with Urologic Cancer
AUA 2024: Impact of 18F-DCFPyL on Accuracy of mpMRI in Men with Low and Intermediate Risk Prostate Cancer: Interim Analysis of a Phase II Diagnostic Trial
AUA 2024: A Phase II Trial of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG-Naïve Non-Muscle Invasive Urothelial Carcinoma of the Bladder
AUA 2024: Comparison of BCG to Gemcitabine/Docetaxel in The Intermediate Risk Group Composed Mostly of TaHG
AUA 2024: The Impact of Delayed Administration of Androgen-Receptor Signaling Inhibitors (ARSI) on Prognosis for mHSPC
AUA 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NMIBC and Quantifies Molecular Response to Nadofaragene Firadenovec
AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: PSMAfore: Efficacy of 177Lu-PSMA-617 Versus ARPI Change in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Pre-Randomization ARPI
AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: Apalutamide and ADT for the Treatment of High-Risk Localized Prostate Cancer Following Radical Prostatectomy in Apa-RP: A Multicenter, Open-Label, Single Arm Trial
AUA 2024: Spatial Analysis of The Tumor Immune Microenvironment in Papillary Renal Cell Carcinoma
AUA 2024: TAR-200 in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 Study
AUA 2024: Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population
AUA 2024: PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patients
31
32
33
34
35
36
37
38
39
40
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free